Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP-KC121E Phase 2 Study in Meibomian Gland Dysfunction
jRCT2031220407Phase 2Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in meibomian gland dysfunction (MGD) comparing KRP-KC121E with Placebo (2 arms). Started Nov 2022; status: completed.
02
Drugs
KRP-KC121E
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on jRCT2031220407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220407.